Cordis, Medinol win FDA nod for Elunir drug-eluting stent

Cordis and Medinol announced today that the FDA approved its EluNir drug-eluting stent for the treatment of patients with narrowing or blocked coronary arteries.

The stent, designed by Medinol and distributed exclusively by Cordis in the U.S., features a novel metallic spring tip and the narrowest strut width of any stent on the market in the U.S., according to the companies.

Get the full story at our sister site, Drug Delivery Business News.

The post Cordis, Medinol win FDA nod for Elunir drug-eluting stent appeared first on MassDevice.

from MassDevice http://ift.tt/2AqJvYe